Recombinant Anti-RUNX2 antibody [EPR14334] (ab192256)
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [EPR14334] (ab192256)](https://www.abcam.com/ps/products/192/ab192256/Images/ab192256-229898-anti-runx2-antibody-epr14334-immunohistochemistry.jpg "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [EPR14334] (ab192256)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR14334] to RUNX2
- Suitable for: IHC-P, ICC/IF, Flow Cyt (Intra)
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-RUNX2 antibody [EPR14334]
See all RUNX2 primary antibodies -
Description
Rabbit monoclonal [EPR14334] to RUNX2 -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, ICC/IF, Flow Cyt (Intra)more details -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat
-
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human osteosarcoma, Human tonsil and Mouse spleen tissues; Saos-2 and PC cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol, 59% PBS, 0.05% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR14334 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab192256 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P | (5) |
1/1000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
| ICC/IF |
1/1000.
For unpurified use at 1/500. |
|
| Flow Cyt (Intra) |
1/50.
|
| Notes |
|---|
|
IHC-P
1/1000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
|
ICC/IF
1/1000. For unpurified use at 1/500. |
|
Flow Cyt (Intra)
1/50. |
Target
-
Function
Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation. -
Tissue specificity
Specifically expressed in osteoblasts. -
Involvement in disease
Defects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies. -
Sequence similarities
Contains 1 Runt domain. -
Domain
A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites. -
Post-translational
modificationsPhosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 860 Human
- Entrez Gene: 12393 Mouse
- Entrez Gene: 367218 Rat
- Omim: 600211 Human
- SwissProt: Q13950 Human
- SwissProt: Q08775 Mouse
- SwissProt: Q9Z2J9 Rat
- Unigene: 535845 Human
see all -
Alternative names
- Acute myeloid leukemia 3 protein antibody
- Alpha subunit 1 antibody
- AML3 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [EPR14334] (ab192256)
Immunohistochemical analysis of paraffin-embedded Mouse spleen tissue labeling RUNX2 with ab192256 at 1/1000 dilution. A ready to use HRP Polymer for Rabbit IgG was used as the secondary. Hematoxylin counterstain.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
![Immunocytochemistry/ Immunofluorescence - Anti-RUNX2 antibody [EPR14334] (ab192256)](https://www.abcam.com/ps/products/192/ab192256/Images/ab192256-273044-anti-runx2-antibody-epr14334-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-RUNX2 antibody [EPR14334] (ab192256)Immunocytochemistry/Immunofluorescence analysis of Saos-2 (Human osteosarcoma cell line) labeling RUNX2 with purified ab192256 at 1/1000 dilution. Cells were fixed with 4% PFA and permeabilized with 0.1% tritonX-100. ab150077 Goat anti rabbit IgG (Alexa Fluor®488) at 1/1000 was used as the secondary antibody. Nuclei were counterstained with DAPI. PBS was used instead of the primary antibody as the negative control.
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [EPR14334] (ab192256)](https://www.abcam.com/ps/products/192/ab192256/Images/ab192256-229901-anti-runx2-antibody-epr14334-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [EPR14334] (ab192256)Immunohistochemical analysis of paraffin-embedded Human osteosarcoma tissue labeling RUNX2 with ab192256 at 1/1000 dilution. A ready to use HRP Polymer for Rabbit IgG was used as the secondary. Hematoxylin counterstain.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
![Flow Cytometry (Intracellular) - Anti-RUNX2 antibody [EPR14334] (ab192256)](https://www.abcam.com/ps/products/192/ab192256/Images/ab192256-272311-anti-runx2-antibody-epr14334-flow-cytometry.jpg)
Flow Cytometry (Intracellular) - Anti-RUNX2 antibody [EPR14334] (ab192256)ab192256 staining RUNX2 in PC-3 (human prostate adenocarcinoma) by intracellular flow cytometry. Cells were fixed with 4% paraformaldehyde, permabilised with 90% methanol and the sample was incubated with the primary antibody at a dilution of 1/50. A goat anti rabbit IgG (Alexa Fluorr® 488) at a dilution of 1/2000 was used as the secondary antibody.
Isoytype control: Rabbit monoclonal IgG (Black)
Unlabelled control: Cell without incubation with primary antibody and secondary antibody (Blue)
-
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [EPR14334] (ab192256)](https://www.abcam.com/ps/products/192/ab192256/Images/ab192256-229900-anti-runx2-antibody-epr14334-immunohistochemistry.jpg)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RUNX2 antibody [EPR14334] (ab192256)Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labeling RUNX2 with ab192256 at 1/1000 dilution. A ready to use HRP Polymer for Rabbit IgG was used as the secondary. Hematoxylin counterstain.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
![Immunocytochemistry/ Immunofluorescence - Anti-RUNX2 antibody [EPR14334] (ab192256)](https://www.abcam.com/ps/products/192/ab192256/Images/ab192256-229895-anti-runx2-antibody-epr14334-immunofluorescence.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-RUNX2 antibody [EPR14334] (ab192256)Immunofluorescent analysis of 4% formaldehyde fixed PC3 cells labeling RUNX2 using ab192256 at a 1/500 dilution. A Goat anti rabbit IgG (Alexa Fluor®488) ab150077 was used as the secondary at a 1/200 dilution. Counterstain DAPI. Permeabilized using 0.1% Triton X-100. The two negative controls: 1. Primary ab concentration (anti-RUNX2) is 1:500 dilution, Secondary ab (Goat anti mouse IgG (Alexa Fluor®594)) is 1:500 dilution; 2. Primary ab concentration (anti-RUNX2) is 1:500 dilution, Secondary ab (Goat anti mouse IgG (Alexa Fluor®594)) is 1:500 dilution.
-
![Anti-RUNX2 antibody [EPR14334] (ab192256)](https://www.abcam.com/ps/products/192/ab192256/Images/ab192256-7-benefits-of-recombinant-antibodies.png)
Anti-RUNX2 antibody [EPR14334] (ab192256)
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (63)
ab192256 has been referenced in 63 publications.
- Alhazmi N et al. Synergistic roles of Wnt modulators R-spondin2 and R-spondin3 in craniofacial morphogenesis and dental development. Sci Rep 11:5871 (2021). PubMed: 33712657
- Li P et al. A bi-layered membrane with micro-nano bioactive glass for guided bone regeneration. Colloids Surf B Biointerfaces 205:111886 (2021). PubMed: 34091371
- Ji H et al. CircRNA hsa_circ_0006215 promotes osteogenic differentiation of BMSCs and enhances osteogenesis-angiogenesis coupling by competitively binding to miR-942-5p and regulating RUNX2 and VEGF. Aging (Albany NY) 13:10275-10288 (2021). PubMed: 33819188
- Kim DK et al. Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation. Nat Commun 12:2527 (2021). PubMed: 33953168
- Xu X et al. SPTBN1 Prevents Primary Osteoporosis by Modulating Osteoblasts Proliferation and Differentiation and Blood Vessels Formation in Bone. Front Cell Dev Biol 9:653724 (2021). PubMed: 33816505